U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Cefotetan - Injection products
  1. Development Resources

Cefotetan - Injection products

Additional FDA-identified interpretive criteria

  Minimum Inhibitory
Concentrations
(mcg/mL)		 Disk Diffusion
(zone diameter in mm)
Pathogen S I R S I R
Haemophilus influenzae ≤4 8 ≥16 - - -

S = Susceptible; I = Intermediate; R = Resistant
Susceptibility interpretive criteria for microorganisms are based on a dosing regimen of 2 grams every 12 hours.

Exceptions to the recognized standard of CLSI M100

  Minimum Inhibitory
Concentrations
(mcg/mL)		 Disk Diffusion
(zone diameter in mm)
Pathogen S I R S I R
Enterobacterales ≤4 8 ≥16 - - -
Anaerobes ≤4 8 ≥16 - - -
Neisseria gonorrhoeae ≤4 8 ≥16 - - -

S = Susceptible; I = Intermediate; R = Resistant
Susceptibility interpretive criteria for microorganisms are based on a dosing regimen of 2 grams every 12 hours

Back to Top